{"id":2752,"date":"2019-05-30T18:57:00","date_gmt":"2019-05-30T18:57:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-reaches-30-2-million-euros-turnover-and-3-37-million-euros-profit-in-the-first-three-months-of-2019\/"},"modified":"2022-07-04T18:59:31","modified_gmt":"2022-07-04T18:59:31","slug":"grindeks-reaches-30-2-million-euros-turnover-and-3-37-million-euros-profit-in-the-first-three-months-of-2019","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-reaches-30-2-million-euros-turnover-and-3-37-million-euros-profit-in-the-first-three-months-of-2019\/","title":{"rendered":"2019. gada pirmaj\u0101 ceturksn\u012b Grindeks sasniedz 30,2 milj. eiro apgroz\u012bjumu un 3,37 milj. eiro pe\u013c\u0146u"},"content":{"rendered":"\n<p>\u0160odien, 30. maij\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2019. gada pirm\u0101 ceturk\u0161\u0146a nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2019. gada pirmaj\u0101 ceturksn\u012b bija 30,2 milj. eiro, kas ir par 4,6 milj. eiro vai par 13% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 ceturksn\u012b. Savuk\u0101rt koncerna pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2019. gada pirmaj\u0101 ceturksn\u012b bija 3,37 milj. eiro, kas, sal\u012bdzinot ar 2018. gada pirmo ceturksni, ir palielin\u0101jusies par 0,17 milj. eiro vai par 5%.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201e\u0145emot v\u0113r\u0101 s\u012bvo farm\u0101cijas industrijas konkurenci, \u012bpa\u0161i m\u016bsu tradicion\u0101lajos tirgos \u2013 Krievij\u0101 un cit\u0101s NVS valst\u012bs, past\u0101v\u012bgi pilnveidojam savu komercpolitiku. Veidojam un stiprin\u0101m sadarb\u012bbu ar aptieku t\u012bkliem, sl\u0113dzam tie\u0161os sadarb\u012bbas l\u012bgumus, t\u0101p\u0113c apgroz\u012bjuma samazin\u0101jumam paredzu \u012bstermi\u0146a raksturu. Turkl\u0101t esam uzlaboju\u0161i koncerna neto pe\u013c\u0146as rentabilit\u0101ti un sasniegu\u0161i 3,37 milj. eiro pe\u013c\u0146as r\u0101d\u012bt\u0101ju, kas sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo ceturksni ir palielin\u0101jies par 5%.\u201d<\/p>\n\n\n\n<p>2019. gada pirmaj\u0101 ceturksn\u012b Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 59 pasaules valst\u012bm kopum\u0101 par 27,9 milj. eiro, kas ir par 4,4 milj. eiro vai par 14% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 ceturksn\u012b.<\/p>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2019. gada pirmaj\u0101 ceturksn\u012b bija 27,5 milj. eiro un ir samazin\u0101jies, sal\u012bdzinot ar 2018. gada pirmo ceturksni, par 4,9 milj. eiro. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2019. gada pirmaj\u0101 ceturksn\u012b veidoja 14,5 milj. eiro, kas ir par 6,9 milj. eiro vai par 32% maz\u0101k nek\u0101 2018. gada pirmaj\u0101 ceturksn\u012b. Sal\u012bdzinot ar 2018. gada pirmo ceturksni, 2019. gada pirmaj\u0101 ceturksn\u012b noz\u012bm\u012bgs p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Kirgizst\u0101n\u0101 par 32%, Arm\u0113nija par 27%, Gruzij\u0101 par 23%, Moldov\u0101 par 19%, Azerbaid\u017e\u0101n\u0101 un Baltkrievij\u0101 par 11%.<\/p>\n\n\n\n<p>Gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs 2019. gada pirmaj\u0101 ceturksn\u012b sasniedza 11,9 milj. eiro, kas ir par 1,2 milj. eiro vai 11% vair\u0101k nek\u0101 2018. gada pirmaj\u0101 ceturksn\u012b.<\/p>\n\n\n\n<p>2019. gada pirmaj\u0101 ceturksn\u012b akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 2,6 milj. eiro, kas ir par 0,57 milj. eiro vai 29% vair\u0101k nek\u0101 2018. gada pirmaj\u0101 ceturksn\u012b. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tika veikts uz ES valst\u012bm, Jap\u0101nu, Kan\u0101du un ASV. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2019. gada pirmaj\u0101 ceturksn\u012b bija deksmedetomid\u012bns, detomid\u012bns un ksilaz\u012bns.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eSekm\u012bgi \u012bstenojam Grindeks koncerna tirgus att\u012bst\u012bbas strat\u0113\u0123iju, un tas pozit\u012bvi atainojas sasniegtajos rezult\u0101tos. Sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo ceturksni, 2019. gada pirmaj\u0101 ceturksn\u012b gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjomu Eiropas Savien\u012bbas valst\u012bs esam palielin\u0101ju\u0161i par 11% un sasniegu\u0161i 11,9 milj. eiro. Eiropas Savien\u012bbas valst\u012bs aug piepras\u012bjums p\u0113c m\u016bsu injekcij\u0101m, k\u0101 ar\u012b sevi\u0161\u0137i v\u0113los izcelt gastroenterolo\u0123ijas medikamenta ursodezoksiholsk\u0101bes kapsulu p\u0101rdo\u0161anas apjoma k\u0101pumu.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160odien, 30. maij\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2019. gada pirm\u0101 ceturk\u0161\u0146a nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2019. gada pirmaj\u0101 ceturksn\u012b&#8230;<\/p>\n","protected":false},"author":3,"featured_media":2749,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2752","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=2752"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/2752\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/2749"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=2752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=2752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=2752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}